It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The current diagnostic biomarkers of acute myocardial infarction (AMI), troponins, lack specificity and exist as false positives in other non-cardiac diseases. Previous studies revealed that cuproptosis, ferroptosis, and immune infiltration are all involved in the development of AMI. We hypothesize that combining the analysis of cuproptosis, ferroptosis, and immune infiltration in AMI will help identify more precise diagnostic biomarkers. The results showed that a total of 19 cuproptosis- and ferroptosis-related genes (CFRGs) were differentially expressed between the healthy and AMI groups. Functional enrichment analysis showed that the differential CFRGs were mostly enriched in biological processes related to oxidative stress and the inflammatory response. The immune infiltration status analyzed by ssGSEA found elevated levels of macrophages, neutrophils, and CCR in AMI. Then, we screened 6 immune-related CFRGs (CXCL2, DDIT3, DUSP1, CDKN1A, TLR4, STAT3) to construct a nomogram for predicting AMI and validated it in the GSE109048 dataset. Moreover, we also identified 5 pivotal miRNAs and 10 candidate drugs that target the 6 feature genes. Finally, RT-qPCR analysis verified that all 6 feature genes were upregulated in both animals and patients. In conclusion, our study reveals the significance of immune-related CFRGs in AMI and provides new insights for AMI diagnosis and treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The First Hospital of Hebei Medical University, Department of Cardiology, Shijiazhuang, China (GRID:grid.452458.a); Hebei Key Laboratory of Heart and Metabolism, Shijiazhuang, China (GRID:grid.452458.a); Handan First Hospital, Department of Cardiology, Handan, China (GRID:grid.452458.a)
2 The First Hospital of Hebei Medical University, Department of Cardiology, Shijiazhuang, China (GRID:grid.452458.a); Hebei Key Laboratory of Heart and Metabolism, Shijiazhuang, China (GRID:grid.452458.a)
3 Handan First Hospital, Department of Cardiology, Handan, China (GRID:grid.452458.a)
4 The First Hospital of Hebei Medical University, Department of Cardiology, Shijiazhuang, China (GRID:grid.452458.a)
5 Hebei Medical University, Department of Biochemistry and Molecular Biology, Shijiazhuang, China (GRID:grid.256883.2) (ISNI:0000 0004 1760 8442)